Winfried Häuser1, Fritjof Bock, Peter Engeser, Thomas Tölle, Anne Willweber-Strumpfe, Frank Petzke. 1. Department of Internal Medicine 1 and Medical Health Care Center (MVZ) Saarbrücken St. Johann, Saarbrücken, Orthopedic Center am grünen Turm, Grüner-Turm-Straße 4-10, Ravensburg, Primary care practice, Hohenzollernstraße 36, Pforzheim and Department of General Practice and Health Services Research at Heidelberg University, Heidelberg, Department of Neurology, Technische Universität München, Munich, Pain Day Hospital and Outpatient Clinic, University of Goettingen, Göttingen.
Abstract
BACKGROUND: The long-term use of opioid analgesic drugs to treat chronic non-cancer pain (CNCP) is a major component of pain pharmacotherapy. The interpretation of the evidence concerning its efficacy and risks is currently debated. METHODS: An interdisciplinary evidence- and consensus-based S3 guideline was updated on the basis of a systematic literature search (CENTRAL, Medline, and Scopus databases, from October 2008 to October 2013); meta-analyses of randomized controlled trials (≥ 4 weeks); and a consensus procedure, as specified by the AWMF regulations, including 22 medical and psychological societies and 2 patient self-help organizations. RESULTS: 119 publications were used to update the guideline, and 6 systematic reviews with meta-analyses were performed. A nominal group process was used to formulate recommendations concerning the indications and contraindications for the treatment of CNCP with opioid analgesics and the manner in which such treatments should be carried out. Opioid analgesics are an option for the short-term treatment (4-12 weeks) of chronic pain due to osteoarthritis (pain intensity, standardized mean difference [SMD]: -0.22 and -0.26), diabetic polyneuropathy (SMD -0.74), post-herpetic neuralgia (SMD -0.58), and chronic low back pain (SMD: -0.29 and -0.74). Long-term opioid treatment (≥ 26 weeks) for these diseases benefits only about 25% of patients. For other conditions, either short- or long-term treatment with opioid analgesics should be considered an individual therapeutic trial. Opioid treatment for pain is contraindicated by primary headaches and by any functional or mental disorder of which pain is a leading manifestation. CONCLUSION: To minimize the risks of opioid analgesic treatment, physicians must be aware of its contraindications and must regularly reassess its efficacy and side effects. Pharmacotherapy should be combined with other types of treatment.
BACKGROUND: The long-term use of opioid analgesic drugs to treat chronic non-cancer pain (CNCP) is a major component of pain pharmacotherapy. The interpretation of the evidence concerning its efficacy and risks is currently debated. METHODS: An interdisciplinary evidence- and consensus-based S3 guideline was updated on the basis of a systematic literature search (CENTRAL, Medline, and Scopus databases, from October 2008 to October 2013); meta-analyses of randomized controlled trials (≥ 4 weeks); and a consensus procedure, as specified by the AWMF regulations, including 22 medical and psychological societies and 2 patient self-help organizations. RESULTS: 119 publications were used to update the guideline, and 6 systematic reviews with meta-analyses were performed. A nominal group process was used to formulate recommendations concerning the indications and contraindications for the treatment of CNCP with opioid analgesics and the manner in which such treatments should be carried out. Opioid analgesics are an option for the short-term treatment (4-12 weeks) of chronic pain due to osteoarthritis (pain intensity, standardized mean difference [SMD]: -0.22 and -0.26), diabetic polyneuropathy (SMD -0.74), post-herpetic neuralgia (SMD -0.58), and chronic low back pain (SMD: -0.29 and -0.74). Long-term opioid treatment (≥ 26 weeks) for these diseases benefits only about 25% of patients. For other conditions, either short- or long-term treatment with opioid analgesics should be considered an individual therapeutic trial. Opioid treatment for pain is contraindicated by primary headaches and by any functional or mental disorder of which pain is a leading manifestation. CONCLUSION: To minimize the risks of opioid analgesic treatment, physicians must be aware of its contraindications and must regularly reassess its efficacy and side effects. Pharmacotherapy should be combined with other types of treatment.
Authors: Teryl K Nuckols; Laura Anderson; Ioana Popescu; Allison L Diamant; Brian Doyle; Paul Di Capua; Roger Chou Journal: Ann Intern Med Date: 2014-01-07 Impact factor: 25.391
Authors: Chiara De Maddalena; Martina Bellini; Marta Berra; Maria Cristina Meriggiola; Anna Maria Aloisi Journal: Pain Physician Date: 2012-07 Impact factor: 4.965
Authors: W Häuser; F Bock; P Engeser; G Hege-Scheuing; M Hüppe; G Lindena; C Maier; H Norda; L Radbruch; R Sabatowski; M Schäfer; M Schiltenwolf; M Schuler; H Sorgatz; T Tölle; A Willweber-Strumpf; F Petzke Journal: Schmerz Date: 2015-02 Impact factor: 1.107
Authors: Jason W Busse; Stefan Schandelmaier; Mostafa Kamaleldin; Sandy Hsu; John J Riva; Per Olav Vandvik; Ludwig Tsoi; Tommy Lam; Shanil Ebrahim; Bradley Johnston; Lori Oliveri; Luis Montoya; Regina Kunz; Anna Malandrino; Neera Bhatnagar; Sohail M Mulla; Luciane C Lopes; Charlene Soobiah; Anthony Wong; Norman Buckley; Daniel Sessler; Gordon H Guyatt Journal: Syst Rev Date: 2013-08-21
Authors: Winfried Häuser; Frederik Wolfe; Peter Henningsen; Gabriele Schmutzer; Elmar Brähler; Andreas Hinz Journal: BMC Public Health Date: 2014-04-13 Impact factor: 3.295
Authors: Jiaxi Lin; Sarah Paganini; Lasse Sander; Marianne Lüking; David Daniel Ebert; Monica Buhrman; Gerhard Andersson; Harald Baumeister Journal: Dtsch Arztebl Int Date: 2017-10-13 Impact factor: 5.594
Authors: Markus B Schumacher; Stefan Jongen; Anja Knoche; Frank Petzke; Eric F Vuurman; Mark Vollrath; Johannes G Ramaekers Journal: Psychopharmacology (Berl) Date: 2017-02-12 Impact factor: 4.530